Apelin promotes diabetic nephropathy by inducing podocyte dysfunction via inhibiting proteasome activities

Caixia Guo a, b, Yu Liu a, Wenjie Zhao a, Shengnan Wei a, Xiaoli Zhang a, Wenying Wang c, Xiangjun Zeng a, *

a Department of Pathophysiology and Pathology, Capital Medical University, Beijing, China
b Department of Cardiology, Beijing Tiantan Hospital, Capital Medical University, Beijing, China
c Department of Urology, Beijing Friendship Hospital, Capital Medical University, Beijing, China

Received: November 28, 2014; Accepted: April 15, 2015

Abstract

Podocyte injuries are associated with progression of diabetic nephropathy (DN). Apelin, an adipocyte-derived peptide, has been reported to be a promoting factor for DN. In this study, we aim to determine whether apelin promotes progression of DN by inducing podocyte dysfunction. Kk-Ay mice were used as models for DN. Apelin and its antagonist, F13A were intraperitoneally administered for 4 weeks, respectively. Renal function and foot process proteins were analysed to evaluate the effects of apelin on kk-Ay mice and podocytes. Apelin increased albuminuria and decreased podocyte foot process proteins expression in kk-Ay mice, which is consistent with the results that apelin receptor (APLNR) levels increased in glomeruli of patients or mice with DN. In cultured podocytes, high glucose increased APLNR expression and apelin administration was associated with increased permeability and decreased foot process proteins levels. All these dysfunctions were associated with decreased 26S proteasome activities and increased polyubiquitinated proteins in both kk-Ay mice and cultured podocytes, as demonstrated by 26S proteasome activation with cyclic adenosine monophosphate (cAMP) or oleuropein. These effects seemed to be related to endoplasmic reticulum (ER) stress, as apelin increased C/EBP homologous protein (CHOP) and p-eIF2α levels while cAMP or oleuropein reduced it in high glucose and apelin treated podocytes. These results suggest that apelin induces podocyte dysfunction in DN through ER stress which was induced by decreased proteasome activities in podocytes.

Keywords: diabetic nephropathy • podocyte • proteasome • ER stress • apelin • APLNR

Introduction

Diabetic nephropathy (DN) is one of the major complications of diabetes mellitus and is the most common cause of end-stage renal diseases [1]. Central to DN progression is glomerular injury [2], which includes injuries of endothelial cells, tubulointerstitial cells, podocytes and mesangial cells, while podocyte injuries are critical in glomerular dysfunction in DN. However, it is disputed that how podocyte is injured in diabetes [3].

Various pathogenic factors have been reported to account for podocyte injuries in DN [4–7]. However, few studies have ever evaluated the actions of adipose tissue on podocyte injuries in DN. The peptide apelin, described as an adipokine due to the production and secretion by isolated mature adipocytes [8], has been reported to be positively related to urinary albumin creatinine ratio (ACR) in diabetic patients [9, 10]. Our previous works also found that apelin displayed promoting effects on DN by enhancing the permeability of glomerular endothelial cells [10]. As emerging evidence suggest that endothelial cell and podocyte injuries in DN are closely related to each other [11], we hypothesized that apelin might promote the podocyte dysfunction in DN as well.

Podocyte injuries consists of apoptosis, detachment, hypertrophy, effacement and loss of foot process proteins [2, 3], of which the intracellular protein regeneration and degradation are the main alterations [12, 13]. The inability of podocytes to properly fold, modify assemble native proteins lead to accumulation of misfolded protein in endoplasmic reticulum (ER) [14]. Under these conditions of ER stress, the ER attempts to restore disrupted homeostasis by inhibiting translation and increasing protein degradation. Multiple systems exist
for proteolysis, the best described of which is the highly conserved non-lysosomal proteolytic ubiquitin-proteasome system (UPS) which degrades ubiquitin-conjugated proteins by proteasomes [15]. Studies have revealed that podocyte injuries were associated with accumulation of monoubiquitinated and polyubiquitinated proteins which resulted from impaired proteasome activities [7, 16]. The proteasome activities could be activated by cAMP [17] and apelin/APLNR has been reported to mainly act through Gαi and decrease cAMP [18]. Therefore, apelin might promote podocyte dysfunction through impairing proteasome activities. The goal of this study was to testify apelin induces podocyte injuries in DN by inhibiting proteasome activities which would result in ER stress.

Materials and methods

Human subjects

Subjects were recruited from inpatients that were operated on kidney because of cancer. The participants have to meet diagnosis criteria of chronic kidney diseases recommended by the Kidney Disease Outcome Quality Initiative [19], simply defined as urine albumin≥300 μg/mg with history of diabetes for at least 1 year. Clinical healthy individuals were negative to urine albumin and no history of known diabetes or kidney disease (serum creatinine, ≤1.4 mg/dl). Exclusion criteria included cardiovascular diseases, cerebrovascular diseases, hypertension, metabolic diseases and inflammatory diseases. We enrolled 20 patients with type 2 diabetes and 20 patients without type 2 diabetes (the detailed information was in Table 1). The study protocol was approved by the ethics committee of Capital Medical University, and informed consent was given by each patient before enrollment. The consent was verbal because the samples were the residues of clinical test specimens. Thus, no extra treatment to the patients was required. The patients signed a sheet that presented the selected cases in table format. The institutional review board of Capital Medical University waived the need for written informed consent from the participants.

Experimental animals

All animal studies followed the Animal Care and Use Committee of Capital Medical University (20100610). All animals received humane care, and the experimental protocol was approved by the Committee of Laboratory Animals according to Institutional guidelines.

The kk-Ay mouse is considered to be a polygenic model for human type 2 diabetes model [20]. It exhibits marked obesity, glucose intolerance, severe insulin resistance, dyslipidaemia and hypertension. Kk-Ay mouse also develops renal disease characterized by moderate albuminuria with mild glomerular pathology and podocyte loss [20, 21]. Male kk-Ay mice and control C57BL/6J at 12 weeks of age mice were purchased from Capital Medical University (Beijing, China). Mice were fed on semi-purified moderately high-fat diet containing 24% kcal fat and 0.2% cholesterol. Mice were randomized according to albumin/creatinine at 12 weeks of age and were killed at 16 weeks of age. C57BL/6J mice were classified as normal control (C57BL), and kk-Ay mice were considered DN when their urine ACR was ≥300 μg/mg. kk-Ay mice were then randomly divided into DN control group (kk group, n = 10), which were intraperitoneally injected with vehicle, apelin treatment group (kk+apelin), which were intraperitoneally injected with apelin-13 (A6469; Sigma-Aldrich, St. Louis, MO, USA, 30 μg/kg/day) for 4 weeks and F13A treatment group (kk+F13A), which were intraperitoneally injected with F13A (Phoenix Pharmaceuticals, Strasbourg France, 25 μg/kg/day) for 4 weeks.

Table 1 The index of enrolled patients with or without type 2 diabetes

|                          | Patients with type 2 diabetes | Patients without type 2 diabetes |
|--------------------------|-------------------------------|---------------------------------|
|                          | Male (n = 11)                 | Female (n = 9)                  |
|                          | Female (n = 10)               | Female (n = 10)                 |
| Age                      | 57.5 ± 6.6                    | 55.6 ± 9.6                      |
|                          | 55.1 ± 8.0                    | 55.7 ± 9.3                      |
| Body mass index (BMI) (kg/m²) | 29.8 ± 2.04                   | 29.7 ± 5.9                      |
|                          | 29.6 ± 3.1                    | 26.4 ± 8.4                      |
| Systolic blood pressure (mmHg) | 135 ± 8.0                     | 130 ± 10                        |
|                          | 130 ± 8.9                     | 130 ± 11                        |
| Diastolic blood pressure (mmHg) | 80 ± 7.0                      | 80 ± 11.5                       |
|                          | 75 ± 10.5                     | 80 ± 11.3                       |
| Triglyceride             | 1.20 ± .023                   | 1.30 ± 0.31                     |
|                          | 1.15 ± 0.26                   | 0.94 ± 0.33                     |
| Cholesterol              | 4.20 ± 0.61                   | 4.32 ± 0.56                     |
|                          | 4.21 ± 0.57                   | 3.57 ± 0.61                     |
| Low density lipoprotein  | 2.60 ± 0.14                   | 2.45 ± 0.21                     |
|                          | 2.53 ± 0.21                   | 2.60 ± 0.22                     |
| High density of lipoprotein | 1.13 ± 0.11                   | 1.25 ± 0.13                     |
|                          | 1.22 ± 0.14                   | 1.26 ± 0.15                     |
| Fasting blood glucose    | 6.61 ± 0.56                   | 7.35 ± 0.53                     |
|                          | 5.35 ± 0.42                   | 5.15 ± 0.23                     |
| Glycosylated haemoglobin | 7.65 ± .68                    | 7.39 ± 0.54                     |
|                          | 5.11 ± 0.35                   | 4.89 ± 0.44                     |
| Albumin creatinine ratio (μg/mg creatinine) | 485 ± 21.5                   | 512 ± 55.3                      |
|                          | 15.9 ± 0.98                   | 15.7 ± 0.87                     |
Biochemical characterization

The level of fasting serum creatinine and fasting bodyweight were measured at the end of the experiments. The urine samples were collected for a period of 24 hrs using a mouse metabolic cage (CLEA Tokyo, Japan). Urinary albumin, and creatinine were measured by immunosay (DCA 2000 system; Siemens AG, Munich, Germany). All analyses were performed in accordance with the manuals provided by the manufacturers. The urinary ACR = urinary albumin (µg)/urinary creatinine (mg). Ccr (Creatinine clearance ratio, ml/min./kg) = [urinary Creatinine (mg/dl) × urinary volume (ml)/serum Creatinine (mg/dl)] × [1000/ bodyweight (g)] × 1/[1440 (min.)].

Pathological examination

Kidneys were excised carefully without any damage and stored in 10% neutral buffered formalin after being washed with PBS. Sections of 5 µm were cut and stained with periodic acid Schiff (PAS) base for pathological observations. An additional aliquot of normal kidney was frozen in optimum cutting temperature compound (OCT) for immunofluorescent staining. A separate aliquot of kidney cortical tissue was cut into 1-mm³ pieces and fixed in 2.5% glutaraldehyde in Millonig solution and embedded in PolyBed 812 (Polysciences Inc., Taipei, Taiwan) for EM (electron microscope) analysis. Glomeruli from 16-week-old male mice from every group were screened on PAS staining. Each animal was evaluated for the presence of glomerular deposits. Deposits were evaluated by giving a grade for the presence of deposits on a scale of one to four: 1 = 25% of the glomerulus; 2 = 25–50%; 3 = 51–75%; 4 = 75% of the glomerulus contains deposits. A total of 50 glomeruli per section were evaluated.

Podocyte cell culture

Conditionally immortalized mouse podocytes, kindly provided by P. Mundel (Mt. Sinai School of Medicine, New York, USA), were cultured as previously described [22]. When podocytes were well-differentiated, they were serum-starved overnight with serum-free DMEM with NG (5.5 mmol/l D-glucose) or high glucose (HG: 25 mmol/l D-glucose) for 24 hrs. Cells were then modulated with apelin (1.0 nmol/l) or F13A (1.0 nmol/l) and 50 µmol/l 8-Br-cAMP (B7880; Sigma-Aldrich) or oleeuropein (0.5 µg/ml, 32619-42-4; Yuanmu Co. Ltd., Shanghai, China) for 48 hrs and harvested for the following assays.

Permeability of podocytes

A modification of a previously published protocol was adopted [23]. Differentiated podocytes were plated on type I collagen coated 24-well transwell plates (P18P01250; Millipore, Carrigtwohill, Ireland). The upper compartment was refilled with 0.25 ml RPMI medium1640 supplemented with 0.5 mg/ml FITC-BSA (FITC labeled bovine serum albumin, A9771; Sigma-Aldrich). The lower compartment was filled with 0.5 ml RPMI medium containing 0.5 mg/ml unlabelled BSA and incubated for 3 hrs at 37°C. FITC-BSA concentration in the lower compartment was determined using a Bio-Tek protein assay (Bio-Tek Laboratories, Hongkong, China) at 492/520 nm absorption/emission wavelengths.

Proteasome activities

The activities of chymotrypsin-like, caspase-like and trypsin-like peptidases of the proteasome were assayed according to modified published protocols [24]. 20 µg protein homogenate was mixed with 25 mmol/l Tris-HCl, pH 7.0, and 40 mmol/l proteasome peptide substrates, up to a total volume of 100 µl, which was then incubated for 1 hr at 37°C. Then, the fluorescence of each solution was monitored by assessing the release of aminoluciferin (AMC) using spectrophotometry (HitachiF-2000; Hitachi Instruments, Tokyo, Japan) at an excitation wavelength of 380 nm and an emission wavelength of 440 nm. All results were standardized to the fluorescence intensity by an equal volume of free AMC (SCP0225; Sigma-Aldrich).

Immunohistochemistry

Tissue sections at 5 µm were used to perform immunostaining for AP-LNR and synaptopodin with rabbit anti APLNR (sc-33823; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and rabbit anti-synaptopodin (sc-50459; Santa Cruz Biotechnology). Second antibodies were donkey anti-rabbit-TR and donkey anti rabbit-HRP. Images were obtained using a microscope (Olympus BX-63, Tokyo, Japan).

Western blotting of protein expression

The proteins from tissues or cells were fractionated by electrophoresis on 10% SDS-PAGE and electro-blotted to polyvinylidene difluoride filter membranes and incubated with the primary antibody at 4°C, and then with a HRP-conjugated secondary antibody. Primary antibodies: rabbit anti-AP-LNR, goat anti-nephrin (sc-32529; Santa Cruz Biotechnology), rabbit anti-synaptopodin (sc-50459; Santa Cruz Biotechnology), rabbit anti-podocin (sc-21009; Santa Cruz Biotechnology), rabbit anti-zonula occludens-1 (ZO-1) (sc-8146; Santa Cruz Biotechnology), rabbit anti-Wilm’s tumor protein (WT1) (sc-192; Santa Cruz Biotechnology), mouse anti-UB (MAB1510; Millipore), rabbit anti-k48-linkage specific polyubiquitinated protein (k48, 8081; Cell Signaling Technology, Danvers, MA, USA), mouse anti-CHOP (2895; Cell Signaling Technology) and rabbit anti-phospho-eIF2α (3398; Cell Signaling Technology). Densitometry was performed with Image J software (NIH, USA). To verify equal loading, antibody to GAPDH was used.

Statistics

Data were summarized as mean ± SD. A p-value less than 0.05 was considered significant. All reported p-values are two-sided. Analyses were carried out using SPSS version 13.0 for the PC (Armonk, NY, USA). Differences between different groups were evaluated for significance using independent t-test or one-way ANOVA and Newman–Keuls post-hoc tests.

Results

The expression and location of APLNR in renal tissue

Prior to exploring the promoting effects of apelin in DN, we performed immuno-staining and Western blotting to examine the protein levels...
of APLNR in kidneys of diabetic human and mice. Immuno-staining detected increased APLNR level in podocytes of type 2 diabetic mice kidney (Fig. 1A). APLNR expression was confirmed by Western blotting analysis in kidneys of mice and patients with DN. APLNR expression was increased in kidney of mice with DN (Fig. 1B) and patients with DN (Fig. 1C).

Apelin replacement aggravated ACR and Ccr

We examined whether apelin aggravated DN or promoted renal dysfunction independently. At the age of 12 weeks old, C57BL and kk-Ay mice showed different ACR (62.3 ± 0.3 µg/mg and 365.3 ± 2.9 µg/mg) and Ccr (1.6 ± 0.01 ml/min/kg and 1.2 ± 0.01 ml/min/kg) with statistical significance and without any significance between C57BL and kk-Ay mice in different groups. After apelin treatment, the ACR was increased from 540 ± 74 µg/mg to 880 ± 41 µg/mg in kk-Ay mice and from 67 ± 4 µg/mg to 136 ± 14 µg/mg in C57BL mice (Fig. 2A). Apelin decreased Ccr from 1.0 ± 0.11 ml/min/kg to 0.57 ± 0.047 ml/min/kg in kk-Ay mice and from 1.60 ± 0.18 ml/min/kg to 1.50 ± 0.15 ml/min/kg in C57BL mice (Fig. 2B). F13A decreased the ACR to 160 ± 18 µg/mg in kk-Ay mice and 56 ± 3 µg/mg in C57BL mice (Fig. 2A). F13A increased Ccr to 1.21 ± 0.047 ml/min/kg in kk-Ay mice and 1.64 ± 0.18 ml/min/kg in C57BL mice (Fig. 2B). These results indicate that increased apelin/APLNR expression might contribute to renal dysfunction independently and aggravate the progression of DN.

The effects of apelin on GBM and podocyte injury

The glomerular pathological changes in DN were characterized by glomerular basement membrane (GBM) thickening and inflammatory cell infiltration. GBM are mainly composed of glycoprotein, collagen and elastin. As shown in Figure 2C, The glomeruli are enlarged, with thickened GBM, and show increased cell numbers and infiltrating leukocytes such as mononuclear cells and lymphocytes in kk-Ay mice. Treatment with apelin aggravated the pathological changes while F13A attenuated them. These results indicate that apelin might aggravate the renal dysfunction in kk-Ay mice by exacerbating the GBM thickening.

The severity of the deposits varied among the groups: C57BL control group (mean: 0.09 ± SE 0.06), kk-Ay mice group (1.18 ± 0.33), kk-apelin group (1.28 ± 0.33) and kk-F13A group (0.6 ± 0.18), and the severity between mice within one group varied as well
Fig. 2 Apelin aggravated renal dysfunction. (A) Apelin significantly increased the albuminuria both in kk-Ay and control mice while F13A reversed it in kk-Ay mice \((n = 10)\). (B) Apelin decreased Ccr in kk-Ay mice while F13A reversed it \((n = 10)\). (C) Representative photographs of kidney section from different groups. Apelin significantly increased the thickening of the GBM and podocyte effacement in kk-Ay mice while F13A reversed it. (D) Scoring of the severity of the deposits in PAS staining of mice in every group. The score represents the mean percentage of the total of 50 glomeruli affected \((\text{grade 0–4}; n = 12)\). (E) Glycaemic levels of the different groups of mice before and after apelin or F13A treatment \((n = 12)\). \(^* p < 0.01\) versus C57BL mice of 12 weeks old, \(^\# p < 0.01\) versus C57BL mice of 16 weeks old, \(^\Delta p < 0.01\) versus kk-Ay mice of 16 weeks old.

© 2015 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
(Fig. 2D). The C57BL and kk-Ay mice were also evaluated at 12 weeks old to study the progression of GBM thickening, showing as C57BL (0.07 ± 0.07) and kk-Ay mice (0.96 ± 0.32), depicting the influence of apelin on GBM thickening.

As podocytes are important for glomerular filtration, we examined foot process with an electronic microscope. Foot process effacement and fusion were aggravated in kk-Ay mice with apelin treatment and prevented with F13A treatment (Fig. 2C). The expression level of foot process proteins including nephrin, podocin, ZO-1, WT-1 and synapotopodin in mice were significantly decreased in kk-Ay mice (to 49%, 59%, 63%, 37% and 51% of C57BL mice, Fig. 3), and apelin treatment further decreased the expression levels of these proteins (to 21%, 23%, 49, 19% and 17% of C57BL mice, Fig. 3) and F13A restored the expression of these proteins (to 73%, 81%, 84%, 58% and 95% of C57BL mice, Fig. 3). These results suggest that apelin levels might be one of the causes of podocyte dysfunction in DN.

**Direct effects of apelin on podocytes**

Podocytes play a major role in the glomerular filtration barrier [25] and podocyte injuries are a key element of DN [26–28]. To confirm the APLNR expression in podocytes, we examined the APLNR expression in cultured podocytes. The expression level of APLNR was increased by high glucose treatment and not changed by apelin treatment in podocytes (Fig. S1). The direct effects of apelin on podocyte permeability and foot process proteins showed that apelin dose-dependently increased the BSA-FITC filtrated through podocytes (Fig. S2A) and decreased foot process proteins in podocytes (Fig. S2B and C). These data indicate a direct action of apelin on podocytes independent of the systemic and/or metabolic aspects.

Furthermore, podocyte permeability was significantly increased with high glucose (by 2.6-fold, Fig. 4A) and apelin (by 4.2-fold, Fig. 4A) treatment. F13A reversed the increasing permeability of podocyte (decreased by 39% compared with HG group, Fig. 4A). These data indicate that apelin might aggravate the podocyte dysfunction in DN.

As foot process proteins are the important functional components of podocytes [29], we examined the expression levels of foot proteins in differentiated podocytes treated with HG and apelin or F13A. The results showed that HG decreased the five foot process proteins: nephrin, podocin, ZO-1, WT-1 and synapotopodin in cultured podocytes (to 48%, 68%, 61%, 75% and 54% of control cells, Fig. 4B and C) and apelin aggravated the decreasing of these proteins (to 23%, 56%, 52%, 53% and 49% of control cells, Fig. 4B and C) while F13A restored it (to 180%, 127%, 74%, 89% and 124% of control cells, Fig. 4B and C). These results suggest that apelin induced the progression of podocyte dysfunction by decreasing the foot process proteins in podocytes.

![Fig. 3](image-url) The effects of apelin on foot process proteins in kk-Ay mice. (A) Representative images of immunostaining for synapotopodin in kidneys. (B) Representative images of western blotting for foot process proteins. (C) Graphs show densitometry of the ratio of nephrin, podocin, ZO-1, WT-1 and synapotopodin to GAPDH in mouse kidney (mean ± SD, n = 3, *p < 0.05).
Because UPS impairment has been reported to be involved in podocyte dysfunction and albuminuria [7, 16], we sought to determine whether apelin regulates proteasome activities in kk-Ay mice. Compared with control group, all of the proteasome activities were decreased by 24%, 34% and 22% (for caspase-like, trypsin-like and chymotrypsin-like activities, Fig. 5B) in kk-Ay mice, as would be expected from the results showing an increased pool of ubiquitinated proteins (by 51% and 60% for ubiquitinated and k48 Linked proteins, Fig. 5A and B). Furthermore, all of the proteasome activities were further decreased by 52%, 60% and 49% (for caspase-like, trypsin-like and chymotrypsin-like activities, Fig. 5C) with apelin treatment and were restored with F13A treatment to 79%, 73% and 76% of control, which were confirmed by increase or decrease of polyubiquitinated proteins (Fig. 5A and B). These results suggest that apelin might aggravate podocyte dysfunction in DN through inhibiting proteasome activities followed with aggregation of polyubiquitinated proteins.

Fig. 4 The effects of apelin on permeability and levels of foot process proteins in podocytes. (A) Albumin permeability was increased by HG and aggravated by apelin while reversed by F13A (n = 6). (B) Representative images of western blotting for foot process proteins in podocytes. (C) Graphs show densitometry of the ratio of nephrin, podocin, ZO-1, WT-1 and synapotopodin to GAPDH in podocytes (n = 3; mean ± SD, *p < 0.05).

Apelin inhibited proteasome activities in kidney

Because UPS impairment has been reported to be involved in podocyte dysfunction and albuminuria [7, 16], we sought to determine whether apelin regulates proteasome activities in kk-Ay mice. Compared with control group, all of the proteasome activities were decreased by 24%, 34% and 22% (for caspase-like, trypsin-like and chymotrypsin-like activities, Fig. 5B) in kk-Ay mice, as would be expected from the results showing an increased pool of ubiquitinated proteins (by 51% and 60% for ubiquitinated and k48 Linked proteins, Fig. 5A and B). Furthermore, all of the proteasome activities were further decreased by 52%, 60% and 49% (for caspase-like, trypsin-like and chymotrypsin-like activities, Fig. 5C) with apelin treatment and were restored with F13A treatment to 79%, 73% and 76% of control, which were confirmed by increase or decrease of polyubiquitinated proteins (Fig. 5A and B). These results suggest that apelin might aggravate podocyte dysfunction in DN through inhibiting proteasome activities followed with aggregation of polyubiquitinated proteins.
Apelin attenuated proteasome activities which was inhibited by HG in podocytes

To evaluate whether apelin directly regulated proteasome activities in podocytes, polyubiquitinated proteins and proteasome activities were assessed in podocytes. Apelin dose-dependently increased polyubiquitinated proteins (Fig. S3A and B) and decreased proteasome activities (Fig. S3C) in podocytes. Polyubiquitinated protein levels were increased by 48% and 21% of control (for ubiquitinated and K48-linked proteins) after HG treatment, and apelin treatment aggravated these increase by 64% and 62% of control (for ubiquitinated and K48-linked proteins) while F13A prevented it by 32% and 18% of control (for ubiquitinated and K48-linked proteins; Fig. 6A and B). Correspondingly, proteasome activities were decreased to 78%, 69% and 40% of control (for caspase-like, tripsin-like and chemotripsin-like activities) after HG treatment, and apelin aggravated these decrease to 61%, 48% and 23% of control (for caspase-like, tripsin-like and chemotripsin-like activities) while F13A prevented it to 108%, 89% and 60% of control (Fig. 6E). These results indicate that apelin impaired the proteasome activities in podocyte of DN.

Among the proteasome subunits, immunoproteasome subunits (β1i, β2i and β5i) are responsible for inducing proteasome activities [30], therefore, we detected the immunoproteasome subunits in cultured podocytes. The results showed that HG decreased the expression levels of β1i, β2i and β5i levels to 54%, 82% and 46% of control, and the reduction was aggravated by apelin to 47%, 52% and 19% of control and restored by F13A to 94%, 98% and 75% of control (Fig. 6C). These results indicate that apelin inhibited the proteasome activities by decreasing the expression levels of immunoproteasome subunits in podocytes.

Role of proteasome activities in podocyte injuries induced by apelin

It has been reported that cAMP stimulates the proteasome activities [31], and apelin act with APLNR to activate Ga_i and decreases cAMP levels. cAMP was added to increase proteasome activities in podocytes. The results showed that HG and apelin induced increasing of polyubiquitinated protein and decreasing of proteasome activities were reversed by cAMP (Fig. S4). The increased permeability of podocytes induced by HG and apelin was reversed by cAMP (to 0.13 ± 0.02 mg/ml, Fig. 7A) and the foot process proteins, nephrin, podocin, ZO-1, WT-1 and synapotopodin, were reversed back (to 89%, 107%, 113% and 120% of normal, Fig. 7B–D). These results suggest that apelin induced podocyte dysfunction in DN through inhibiting cAMP.

Besides activating proteasomes, cAMP possesses much more potential functions in cells [32–34]. To prove that inhibiting proteasome activities is one of the key pathways induced by apelin, which will lead to podocyte injures in DN, we used oleuropein to activate proteasome activities [35, 36] to find whether the podocyte injuries induced by apelin were reversed or not. The results showed that oleuropein restored the foot process proteins, nephrin, podocin, ZO-1, WT-1 and synapotopodin, decreased by HG and apelin (to 72%, 91%,...
104%, 90% and 115% of normal, Fig. 7B–D). These results indicate that apelin aggravate podocyte injuries in diabetes by inhibiting proteasome activities.

**ER stress was induced by decreased proteasome activities in podocytes**

Among the pathways implicated in UPS action, ER stress appears to have a major role for kidney dysfunction [16]. The baseline ER stress markers, phospho-eIF2α and CHOP, in differentiated podocytes were increased by high glucose and were further increased by addition of apelin, but the increase was prevented by cAMP or oleuropein (Fig. 8). These results suggested that apelin aggravated podocyte injuries by inducing ER stress which was caused by decreased proteasome activities.

**Discussion**

We had reported that apelin concentration in serum and kidney was increased in DN [10]. In the present study, we reported that APLNR level was increased within the glomeruli in patients and mice with DN, and apelin aggravated ACR, Ccr and GBM thickening in kk-Ay mice, from which we concluded that excessive apelin/APLNR contributes to renal dysfunction in DN. As apelin is an adipokine and could be increased with body mass [8], therefore, these effects might be present in obese chronic kidney disease too. However, it is controversial that apelin/APLNR induce or prevent the progression of DN [9, 10, 37]. As podocyte dysfunction is critical in renal dysfunction of DN [29], we aimed to verify the effects of apelin/APLNR on podocyte dysfunction in DN.

First of all, we detected the effects of apelin on glomerular filtration. The results found that microalbuminuria and podocyte foot process effacement were aggravated by treatment with apelin and abrogated via treatment with F13A as shown in Figure 2C and D. Furthermore, foot process proteins were further down-regulated by apelin and extenuated by F13A in kk-Ay mice as shown in Figure 3. These effects were confirmed by cultured podocytes, which showed that apelin decreased the expression of foot process proteins in podocytes and increased the FITC-BSA filtrating through monolayered podocytes as shown in Figure 4. These results suggest that apelin/APLNR does contribute to glomerular filtration membrane injuries through aggravating podocyte injuries in DN.

Then, the problem is how apelin/APLNR induces the podocyte injuries. Apelin/APLNR is reported to inhibit cAMP by activating Gαi
[38], and cAMP has been reported to increase the UPS activities [31]. The UPS selectively degrades damaged or abnormal proteins [39], and sometimes the proteasome might be impaired or ‘choked’ by certain factors [16] which will induce the ER stress. And the ER stress has been reported to be responsible for podocyte injuries [40, 41]. Therefore, we assume that apelin/APLNR might impair the proteasome by inhibiting cAMP and induce the ER stress in podocyte to aggravate the progression of DN.

Our results showed that apelin increased the polyubiquitinated proteins in kk-Ay mice while F13A restored it. At the same time, an even more reduction in proteasomal enzymatic activities in kk-Ay mice was observed after apelin treatment (as shown in Fig. 5). These results suggest that impairing proteasome activities may contribute to the apelin-aggravated podocyte injuries in DN. Meanwhile, we also observed that apelin increased polyubiquitinated proteins and decreased proteasome activities in cultured podocytes (as shown in Fig. 6A, B and E). These results imply that decreased proteasome activities in podocytes, which are associated with increased ubiquitinated proteins content, might be the key pathway involved in apelin induced podocyte injury in DN. These results are consistent with the podocyte injury in rat membrane nephropathy [7].

To validate how apelin decreases the proteasome activities in podocytes, we detected the expression of immunoproteasome subunits (β1i, β2i and β5i) in podocytes. The results showed that apelin further reduced β1i, β2i and β5i levels decreased by HG (as shown in Fig. 6C and D). These results suggest that apelin inhibits the proteasome activities by decreasing the levels of immunoproteasome subunits in podocytes.

Then, what intermediates apelin/APLNR reduced proteasome activities? cAMP has been reported to stimulate the proteasome

Fig. 7 Apelin aggravated podocytes injuries through inhibiting proteasome activities. (A) Apelin increased the albumin permeability of podocytes treated with HG, which was inhibited by cAMP (n = 6). (B) Representative images of western blotting for foot process proteins in podocytes. (C) Graphs show densitometry of the ratio of nephrin, podocin, ZO-1, WT-1 and synapotopodin to GAPDH in podocytes (n = 3). (D) Representative images of immunostaining for synapotopodin in podocytes (mean ± SD, *p < 0.05).
Fig. 8 Apelin stimulated endoplasmic reticulum stress in podocytes, which was inhibited by cAMP or oleuropein. (A and C) Representative images of western blotting for eIF2α and CHOP. (B and D) Graphs show densitometry of the ratio of eIF2α and CHOP to GAPDH in podocytes (mean ± SD, n = 3, *p < 0.05 versus control group, #p < 0.05 versus HG treated group).
activities [31], and apelin acts with APLNR to activate Gαi and decrease cAMP levels. Therefore, we assumed cAMP as the mediation for apelin/APLNR and proteasome activities. The results showed that cAMP reversed the increased BSA-FITC filtration and decreased foot process proteins in apelin treated podocytes (as shown in Fig. 7). Thus, we conclude that decreased cAMP levels in podocytes by apelin mediates the inhibition of proteasome activities and results in podocyte dysfunction.

The remaining problem is how the dysfunction of proteasome leads to podocyte injury. Recent studies imply that complement-induced podocyte injury is associated with protein misfolding in the ER, and the enhancement of ER chaperoning capacity reduces injuries [42, 43]. Under ER stress, variety of proteins were up-regulated or phosphorated to restore ER homestasis [14, 44]. We detected CHOP and phosphorated of eIF2α, and the results indicated that CHOP and p-eIF2α levels were increased by apelin in high glucose treated podocytes (as shown in Fig. 8A). These effects were reversed by activation of proteasome activities with cAMP (as shown in Fig. 8B). These findings confirmed us that apelin induced podocyte dysfunctions in DN might be due to the apelin triggered ER stress. There are other ER stress proteins [45, 46], such as GRP78, GRP94 and ORP150, which were reported to be involved in podocyte injury. Whether the other ER stress proteins were involved in apelin/APJ induced podocyte injury needs more further studies.

However, there are many other effects that could be induced by cAMP besides stimulating proteasome activities [32–34]. To verify that proteasome is the downstream pathway in apelin treated podocytes, we used oleuropein to activate proteasome and found that both foot process proteins and ER stress markers were reversed just like the effects of cAMP (as shown in Figs 7B, C and 8C, D). These results suggest that apelin/APLNR decrease proteasome activities by inhibiting cAMP.

In conclusion, apelin/APLNR contributes to albuminuria in DN. Apelin plays a promoting role to enhance albuminuria by directly affecting podocyte function via inhibiting the proteasome activities which subsequently induced ER stress. Our results provide a pathological evidence for the apelin-proteasome-ER stress pathway to promote albuminuria and potentially affect early DN. Therefore, apelin/APLNR might be a potential target for preventing the progression of DN.

**Acknowledgement**

This work was supported by the Natural Science Foundation of China grant no. 81270815.

**Conflicts of interest**

The authors confirm that there are no conflicts of interest.

**Supporting information**

Additional Supporting Information may be found in the online version of this article:

**Figure S1** (A) The immunohistochemical assay of APLNR expression in podocytes.

**Figure S2** Effects of apelin on podocyte permeability and foot process proteins expression in podocytes.

**Figure S3** Apelin impairs proteasome peptidase activities in podocytes.

**Figure S4** CAMP reversed the proteasome activity which was inhibited by apelin.

**References**

1. Maezawa Y, Takemoto M, Yokote K. Cell biology of diabetic nephropathy: roles of endothelial cells, tubulointerstitial cells and podocytes. *J Diabetes Investig*. 2013; 6: 3–15.

2. Stiegler N, Worthmann K, Schiffer M. The role of metabolic and haemodynamic factors in podocyte injury in diabetes. *Diabetes Metab Res Rev*. 2011; 27: 207–15.

3. Barisoni L. Podocyte biology in segmental sclerosis and progressive glomerular injury. *Adv Chronic Kidney Dis*. 2012; 19: 76–83.

4. Daroux M, Prevost G, Maillard-Lefebvre H, et al. Advanced glycation end-products: implications for diabetic and non-diabetic nephropathies. *Diabetes Metab*. 2010; 36: 1–10.

5. Taniguchi K, Xia L, Goldberg HJ, et al. Inhibition of Src kinase blocks high glucose-induced EGFR transactivation and collagen synthesis in mesangial cells and prevents diabetic nephropathy in mice. *Diabetes*. 2013; 62: 3874–86.

6. Sullivan T, Miao Z, Dairagi D, et al. CCR2 antagonist CCX140-B provides renal and glycemic benefits in diabetic transgenic human CCR2 knock-in mice. *Am J Physiol Renal Physiol*. 2013; 305: F1288–F1297.

7. Meyer-Schwesinger C, Greka A, Mundel P. Ubiquitin C-terminal hydrolase-1 activity induces polyubiquitin accumulation in podocytes and increases proteinuria in rat membranous nephropathy. *Am J Pathol*. 2011; 178: 2044–57.

8. Castan-Laurell I, Drey C, Attane C, et al. Apelin, diabetes, and obesity. *Endocrine*. 2011; 40: 1–9.

9. Day RT, Cavaglieri RC, Feliers D. Apelin retards the progression of diabetic nephropathy. *Am J Physiol Renal Physiol*. 2013; 304: F788–800.

10. Zhang BH, Wang W, Wang H, et al. Promoting effects of the adipokine, apelin, on diabetic nephropathy. *PLoS ONE*. 2013; 8: e60457.

11. Tufro A, Veron D. VEGF and podocytes in diabetic nephropathy. *Semin Nephrol*. 2012; 32: 385–93.

12. Greka A, Mundel P. Cell biology and pathology of podocytes. *Annu Rev Physiol*. 2012; 74: 299–323.

13. Fougeray S, Pallet N. Mechanisms and biological functions of autophagy in diseased ageing kidneys. *Nat Rev Nephrol*. 2015; 11: 34–45.
14. Malý DJ, Papa FR. Druggable sensors of the unfolded protein response. *Nat Chem Biol*. 2014;10: 892–901.
15. Hochstrasser M. Ubiquitin, proteasomes, and the regulation of intracellular protein degradation. *Curr Opin Cell Biol*. 1995;7: 215–23.
16. Cybulsky AV. The intersecting roles of endoplasmic reticulum stress, ubiquitin-proteasome system, and autophagy in the pathogenesis of proteinuric kidney disease. *Kidney Int*. 2012;84: 25–33.
17. Drews O, Tsukamoto O, Liem D, et al. Differential regulation of proteasome function in isoproterenol-induced cardiac hypertrophy. *Circ Res*. 2010;107: 1094–101.
18. Moon MJ, Oh DY, Moon JS, et al. Cloning and activation of the bullfrog apelin receptor: G/o coupling and high affinity for [Pro1]apelin-13. *Mol Cell Endocrinol*. 2007;277: 51–60.
19. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. *Am J Kidney Dis*. 2002;39: S1–266.
20. Tomino Y. Lessons from the KK-Ay mouse, a spontaneous animal model for the treatment of type 2 diabetic nephropathy. *Nephron Mon*. 2012;4: 524–9.
21. O'Brien SP, Smith M, Ling H, et al. Glomerulopathy in the KK.Cg-Ay/J mouse reflects the pathology of diabetic nephropathy. *J Diabetes Res*. 2013;2013: 498925.
22. Mundel P, Reiser J, Zuniga Mejia Borja A, et al. Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. *Exp Cell Res*. 1997;236: 248–58.
23. Rico M, Mukherjee A, Konieczkowski M, et al. WT1-interacting protein and ZO-1 translocate into podocyte nuclei after puromycin aminonucleoside treatment. *Am J Physiol Renal Physiol*. 2005;289: F431–41.
24. Tian Z, Zheng H, Li J, et al. Genetically induced moderate inhibition of the proteasome in cardiomyocytes exacerbates myocardial ischemia-reperfusion injury in mice. *Circ Res*. 2012;111: 532–42.
25. Kriz W, Kretzler M, Provoost AP, et al. Stability and leakiness: opposing challenges to the glomerulus. *Kidney Int*. 1996;49: 1570–1574.
26. Koh JH, Lee ES, Hyun M, et al. Taurine alleviates the progression of diabetic nephropathy in type 2 diabetic rat model. *Int J Endocrinol*. 2014;2014: 397307.
27. Reidy K, Kang HM, Hostetter T, et al. Molecular mechanisms of diabetic kidney disease. *J Clin Invest*. 2014;124: 3333–40.
28. Carney EF. Diabetic nephropathy: cholesterol and podocyte injury. *Nat Rev Nephrol*. 2013;9: 493.
29. Schiewek D, Endlich N, Holzman L, et al. Stable expression of nephrin and localization to cell-cell contacts in novel murine podocyte cell lines. *Kidney Int*. 2004;66: 91–101.
30. Coppo R, Camilla R, Alfarrano A, et al. Upregulation of the immunoproteasome in peripheral blood mononuclear cells of patients with IgA nephropathy. *Kidney Int*. 2009;75: 536–41.
31. Drews O, Tsukamoto O, Liem D, et al. Differential regulation of proteasome function in isoproterenol-induced cardiac hypertrophy. *Circ Res*. 2010;107: 1094–101.
32. Xiao Z, He L, Takemoto M, et al. Glomerular podocytes express type 1 adenylate cyclase: inactivation results in susceptibility to proteinuria. *Nephron Exp Nephrol*. 2011;118: e39–48.
33. Jiang L, Xu L, Song Y, et al. Calmodulin-dependent protein kinase II/CAMP response element-binding protein/Wnt/beta-catenin signaling cascade regulates angiotsin II-induced podocyte injury and albuminuria. *J Biol Chem*. 2013;288: 23368–79.
34. Azeloglu EU, Hardy SV, Eungdamrong NJ, et al. Interconnected network motifs control podocyte morphology and kidney function. *Sci Signal*. 2014;7: r12.
35. Omar SH. Oleuropein in olive and its pharmacological effects. *Sci Pharm*. 2010;78: 153–54.
36. Katsiki M, Chondrogiani N, Chinou I, et al. The olve constituent oleuropein exhibits proteasome stimulatory properties in vitro and confers life span extension of human embryonic fibroblasts. *Rejuvenation Res*. 2007;10: 157–72.
37. Chen H, Li J, Jiao L, et al. Apelin inhibits the development of diabetic nephropathy by regulating histone acetylation in Akita mouse. *J Physiol*. 2014;592: 505–21.
38. Li Y, Chen J, Bai B, et al. Heterodimerization of human apelin and kappa opioid receptors: roles in signal transduction. *Cell Signal*. 2012;24: 991–1001.
39. Fukasawa H. The role of the ubiquitin-proteasome system in kidney diseases. *Clin Exp Nephrol*. 2012;16: 507–17.
40. Inagi R. Endoplasmic reticulum stress in the kidney as a novel mediator of kidney injury. *Nephron Exp Nephrol*. 2009;112: e1–9.
41. Pallet N, Bouvier N, Beaune P, et al. Endoplasmic reticulum stress in kidney diseases: a question of life and death? *Nephrol Ther*. 2009;5: 173–80.
42. Cybulsky AV. Endoplasmic reticulum stress in proteinuric kidney disease. *Kidney Int*. 2010;77: 187–93.
43. Luo ZF, Qi W, Feng B, et al. Prevention of diabetic nephropathy in rats through enhanced renal antioxidative capacity by inhibition of the proteasome. *Life Sci*. 2011;88: 512–20.
44. Okamura M, Takano Y, Hiramatsu N, et al. Suppression of cytokine responses by indomethacin in podocytes: a mechanism through induction of unfolded protein response. *Am J Physiol Renal Physiol*. 2008: 295: F1495–503.
45. Inagi R, Nangaku M, Onogi H, et al. Involvement of endoplasmic reticulum (ER) stress in podocyte injury induced by excesive protein accumulation. *Kidney Int*. 2005;68: 2639–50.
46. Wang L, Hong Q, Lv Y, et al. Autophagy can repair endoplasmic reticulum stress damage of the passive Heymann nephritis model as revealed by proteomics analysis. *J Proteomics*. 2012;75: 3866–78.